Published in Cancer Weekly, August 16th, 1999
C.A. Aarnoudse and colleagues from the University of Leiden, The Netherlands, discovered a new tumor antigen which they dubbed CAMEL, which is short for CTL-recognized antigen on melanoma. The finding was reported in a recent issue of the International Journal of Cancer ("Interleukin-2-Induced, Melanoma-Specific T Cells Recognize Camel, An Unexpected Translation Product of LAGE-1," International Journal of Cancer, July 30, 1999;82(3):442-448).
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.